Patents Assigned to Viacyte, Inc.
  • Patent number: 12234477
    Abstract: The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 25, 2025
    Assignee: ViaCyte, Inc.
    Inventor: Thomas C Schulz
  • Publication number: 20250032672
    Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.
    Type: Application
    Filed: October 10, 2024
    Publication date: January 30, 2025
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Patent number: 12173323
    Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: December 24, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
  • Publication number: 20240409900
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Application
    Filed: January 18, 2024
    Publication date: December 12, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Patent number: 12144908
    Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: November 19, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Publication number: 20240299462
    Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Kevin Allen D'Amour
  • Publication number: 20240245481
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Application
    Filed: February 7, 2024
    Publication date: July 25, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Publication number: 20240218324
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Application
    Filed: September 26, 2023
    Publication date: July 4, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Allan J. Robins, Thomas C. Schulz
  • Publication number: 20240165212
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Application
    Filed: September 21, 2023
    Publication date: May 23, 2024
    Applicant: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 11925488
    Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: March 12, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
  • Patent number: 11920154
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: March 5, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Allan J Robins, Thomas C Schulz
  • Patent number: 11904001
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 20, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 11905530
    Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 20, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schulz
  • Patent number: 11896622
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 13, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Publication number: 20230293812
    Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 21, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
  • Patent number: 11746323
    Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: September 5, 2023
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
  • Publication number: 20230256137
    Abstract: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.
    Type: Application
    Filed: April 25, 2023
    Publication date: August 17, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
  • Publication number: 20230233739
    Abstract: Disclosed are cell encapsulation devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. In some examples, a cell encapsulation can comprise a lumen configured to receive cells therein, a cell-excluding membrane, where the lumen is internal to the cell-excluding membrane, and a non-woven fabric layer external to the cell-excluding membrane, where the non-woven fabric layer and the cell-excluding membrane comprise perforations. The device can further comprise a woven mesh external to the non-woven fabric layer, where the non-woven fabric layer provides protection to the cell-excluding membrane from direct contact with the woven mesh.
    Type: Application
    Filed: March 2, 2023
    Publication date: July 27, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Patent number: 11667889
    Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 6, 2023
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge
  • Publication number: 20230165908
    Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
    Type: Application
    Filed: August 24, 2022
    Publication date: June 1, 2023
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Kevin Allen D’Amour